The chronic activation of the
Janus kinase/signal transducer and activator of the transcription (JAK/STAT) pathway is linked to oxidative stress,
inflammation and cell proliferation. Suppressors of
cytokine signaling (
SOCS) proteins negatively regulate the JAK/STAT, and SOCS1 possesses a small
kinase inhibitory region (KIR) involved in the inhibition of
JAK kinases. Several studies showed that KIR-SOCS1 mimetics can be considered valuable
therapeutics in several disorders (e.g., diabetes,
neurological disorders and
atherosclerosis). Herein, we investigated the
antioxidant and atheroprotective effects of PS5, a
peptidomimetic of KIR-SOCS1, both in vitro (vascular smooth muscle cells and macrophages) and in vivo (
atherosclerosis mouse model) by analyzing gene expression, intracellular O2•- production and
atheroma plaque progression and composition. PS5 was revealed to be able to attenuate
NADPH oxidase (NOX1 and NOX4) and pro-inflammatory gene expression, to upregulate
antioxidant genes and to reduce
atheroma plaque size,
lipid content and monocyte/macrophage accumulation. These findings confirm that KIR-SOCS1-based drugs could be excellent
antioxidant agents to contrast
atherosclerosis.